Loading
Hereditary papillary renal cell carcinoma is a rare inherited condition, caused by an activating change in the MET gene, that carries a very high lifetime risk of papillary kidney cancer. It is managed by kidney specialists with experience of inherited kidney cancer.
Autosomal dominant, caused by activating germline variants in the MET proto-oncogene (the hepatocyte growth factor receptor). The NCI PDQ summary of kidney cancer genetics lists papillary renal cell carcinoma (formerly type 1) as the tumour, a cumulative cancer risk approaching 100%, and no associated non-renal tumours. Clinical genetic tests for MET are available in CLIA-certified laboratories, and genetic counselling is a prerequisite.
No management guideline specific to this syndrome was read in this round: the PDQ summary gives no surveillance schedule, so none is recorded.
In plain words · A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail.
Showing the target this term concerns: MET.
Shares Hereditary cancer syndromes, Germline (hereditary) testing and the tag hereditary.
Shares Hereditary cancer syndromes, Germline (hereditary) testing and the tag hereditary.
Shares Hereditary cancer syndromes, Germline (hereditary) testing and the tag hereditary.
Shares Hereditary cancer syndromes, Germline (hereditary) testing and the tag hereditary.
Shares Hereditary cancer syndromes, Germline (hereditary) testing and the tag hereditary.
Shares Hereditary cancer syndromes, Germline (hereditary) testing and the tag hereditary.
Shares Hereditary cancer syndromes, Germline (hereditary) testing and the tag hereditary.
Shares Hereditary cancer syndromes, Germline (hereditary) testing and the tag hereditary.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/